ReviewThe Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology2026
Effects of Gilbert syndrome on cardiovascular disease risk reduction: a systematic review.
Review in The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGilbert syndrome is a human genetic disorder which affects bilirubin metabolism in the liver and results in unconjugated hyperbilirubinemia. While considered a benign condition with only occasional jaundice and possible alterations of metabolism of certain drugs, Gilbert syndrome can reduce cardiovascular disease (CVD) risk. The objective of this review was to summarize the evidence on the potential effect of Gilbert Syndrome on reducing CVD risk via lowering cholesterol and/or lipid levels in the body and is associated with other protective mechanisms which are related to higher blood levels of unconjugated bilirubin.
methodsA systematic review of articles returned from the online database PubMed was conducted using search terms: "Gilbert syndrome", "reduced cardiovascular disease risk", "cardiovascular disease", "cholesterol", and "lipid level".
resultsAfter filtering using the exclusion criteria and removing duplicates, eight articles were identified for the review. This review found that CVD risk was lower for people with Gilbert syndrome when compared to unaffected individuals. The reduced CVD risk was theorized to be due to elevated unconjugated bilirubin levels which lead to reduced concentrations of lipids, reduced inflammation biomarkers, decreased ABCA1 protein, increased serum antioxidant capacity expression, decreased BMI, and lower triglyceride levels.
conclusionIndividuals with Gilbert syndrome have a reduced CVD risk. Given that Gilbert syndrome reduces CVD risk in individuals and that Gilbert syndrome results in elevated serum levels of unconjugated bilirubin; elevation of unconjugated bilirubin could serve as a biomarker to monitor CVD risk reduction in the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.